Sri Lanka’s contraceptive supply chain is facing a serious disruption as pharmacies, clinics and private healthcare providers experience shortages caused by a regulatory and pricing impasse.
The crisis has developed around maximum retail price controls imposed by the National Medicines Regulatory Authority (NMRA), which have reportedly left importers caught between regulated selling prices and rising international procurement costs. With the commercial equation becoming increasingly difficult, local importers stopped placing fresh orders, creating a supply vacuum that has now extended into both private and public healthcare channels.
The consequences reach far beyond empty pharmacy shelves. More than 54% of women of reproductive age in Sri Lanka rely on modern family-planning methods, making uninterrupted contraceptive availability an important component of reproductive healthcare.
The scale of demand is demonstrated by the estimated three million emergency contraceptive pills consumed annually by Sri Lankan women. Any prolonged interruption therefore has the potential to affect a substantial number of households and women who depend on these products to prevent unintended pregnancies.
A breakthrough has emerged through the Family Planning Association of Sri Lanka, which has negotiated with regulators to obtain emergency permission to import essential contraceptive supplies directly from Bangladesh. The move could provide short-term relief, but it also exposes a deeper vulnerability within Sri Lanka’s medicine-importation system.
Sri Lanka depends heavily on imported medicines and medical supplies, with around 80% of total medical supplies coming from overseas sources. Consequently, disruptions involving international prices, foreign exchange, regulatory approvals, import financing or domestic price controls can rapidly translate into shortages at the consumer level.
The present episode raises questions about whether the existing pricing mechanism adequately reflects changing global procurement costs while protecting consumers from excessive prices.
For importers, a regulated maximum retail price can become commercially unsustainable if international purchase prices, freight costs, currency movements and other expenses rise substantially. For patients, however, removing price protection can create another barrier to access.
The challenge for regulators is therefore to maintain affordability without creating conditions that discourage legitimate suppliers from bringing essential medicines into the country.
The contraceptive shortage also highlights a wider public-health risk. Because abortion remains legally restricted in Sri Lanka except where necessary to save the life of the mother, reduced access to contraception does not remove the demand for pregnancy prevention.
Instead, prolonged shortages could increase the risk of unintended pregnancies and potentially expose vulnerable women to unsafe or illegal alternatives.
Sri Lanka’s extensive network of public-health midwives and family-planning services has helped establish reproductive healthcare access over decades. Sustaining that achievement requires not only emergency imports but a resilient procurement and pricing system capable of preventing repeated stockouts.
The Bangladesh arrangement may therefore solve an immediate shortage. The larger question is whether authorities can address the regulatory and commercial weaknesses that allowed an essential reproductive-health supply chain to reach breaking point